Novofem

Quick links to important sections

Novofem

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novofem

Novofem is a highly structured, prescription-only pharmaceutical preparation formulated to provide hormonal supplementation to postmenopausal women who have an intact uterus. It is manufactured by Novo Nordisk Limited, positioning it as a distinct brand within the broader market of Hormone Replacement Therapy (HRT).


Property Description
Active ingredients Estradiol (as hemihydrate), Norethisterone (as acetate)
Form Film-coated tablets (two-color regimen)
Pharmacological class Estrogens and progestogens (sequential preparations)
Common use Addressing postmenopausal hormone deficit
Origin Synthetic/Semi-synthetic hormonal compounds

What Type of Medicine is Novofem and What is it Made of?

Novofem is a combination product that contains two primary active ingredients: Estradiol and Norethisterone. Its official pharmacological classification is Progestagens and oestrogens, sequential preparations (ATC code G03FB05), a designation that confirms its defined role in managing hormonal balance through phased delivery. The dual-hormone structure is clinically recognized as necessary for women with an intact uterus, as the progestogen component is included for endometrial protection, mitigating the risk of excessive uterine lining growth caused by unopposed estrogen.

What is the Form and Structure of Novofem?

The physical form of Novofem is film-coated tablets designed for oral intake, packaged in a distinctive 28-day calendar pack that aids in adherence to the regimen. Its key differentiating structural feature is the sequential combined regimen: the pack contains tablets with only Estradiol, followed by tablets containing both Estradiol and Norethisterone acetate. This sequenced approach is specifically intended for cyclical HRT, which typically results in a monthly withdrawal bleed.

What is the General Therapeutic Purpose of Novofem?

The general therapeutic purpose of Novofem is to provide hormonal supplementation that directly addresses the systemic oestrogen deficiency arising post-menopause. By substituting the lost hormones, the therapy is designed to re-establish a more functional hormonal balance in the body, which is the foundational therapeutic strategy for supporting the overall well-being of the postmenopausal women for whom the therapy is indicated.

What side effects are possible with Novofem?

The official safety profile for Novofem, a combined sequential Hormone Replacement Therapy (HRT) product, is strictly defined by regulatory documents, which list potential adverse reactions by category, frequency, and severity. This information establishes the formal constraints and monitored risks associated with the medicine.

Adverse Reaction Scope

Category Regulatory Summary
Key Adverse Reaction Categories Neoplasms; Vascular Disorders; Reproductive System; Nervous System; Hepatobiliary Disorders.
Common Side Effects Breast tenderness, headache, fluid retention, weight gain, and breakthrough bleeding or spotting.
Serious Adverse Reactions Officially documented serious risks include Venous Thromboembolism (VTE), Stroke, Myocardial Infarction, and an increased risk of Breast and Endometrial Cancer [FDA Label, HPRA SmPC].
Population-Specific Notes The progestogen component is required for endometrial protection in women with an intact uterus. An increased risk of probable dementia is documented when combined HRT is initiated in women aged 65 years and older [FDA Label].
Exposure-Related Patterns The risk of VTE is documented as being highest during the first year of use. Breakthrough bleeding or spotting is more common during the initial months of treatment [HPRA SmPC].
Safety-Related Restrictions The medicine is strictly contraindicated in conditions such as known or suspected breast cancer, active liver disease, untreated endometrial hyperplasia, and a history of VTE or arterial thromboembolic disease [SAHPRA SmPC].

Connection to the Overall Safety Profile

The regulatory safety data formally classifies systemic risks (vascular events and malignancies) alongside common, expected reactions, defining the necessary monitoring and absolute restrictions on use. This framework focuses on documenting official safety statements and constraints for this class of medicine, particularly noting risks associated with duration and age.

Overdose and Emergency Response

The regulatory profile for Novofem overdose provides specific documentation regarding manifestations and mandated management protocols. Authorities state that serious symptoms are very unlikely to occur following an overexposure to this sequential hormonal product. The classification of severity is low, and the immediate concern focuses on non-severe, expected hormonal effects.

Official Manifestations and Action

The documented clinical manifestations of overdose are typically non-serious. These may include signs affecting the reproductive and gastrointestinal systems, such as nausea, vomiting, breast enlargement, and vaginal bleeding (metrorrhagia). Upon suspicion of having taken a dose larger than prescribed, the regulatory requirement is to talk to a doctor or pharmacist immediately for consultation.

Management Protocol and Constraints

The mandated emergency response emphasizes a non-specific approach: any necessary treatment must be symptomatic and supportive. This approach is required because no specific antidote is known for the combination of estradiol and norethisterone acetate. In documented scenarios of large overdosage, and provided the individual is seen early, procedural steps such as gastric lavage may be employed. The official labeling does not specify distinct overdose risks or management for special populations.

Therapeutic Uses of Novofem

Novofem is a type of Hormone Replacement Therapy (HRT), generally applied across domains where additional symptomatic support is needed for women following menopause. It is relevant in contexts involving heightened systemic burden in postmenopausal women.

The main therapeutic indication is the treatment of symptoms associated with estrogen deficiency in postmenopausal women. These are symptoms related to systemic imbalance that can include vasomotor manifestations like hot flushes and night sweats, as well as urogenital discomfort. The medication is also relevant for easing the overall symptom burden associated with these changes.

Novofem is a continuous sequential product where the combined components support the required therapeutic action. The product's formulation is applied across conditions where functional stability becomes affected. It is commonly used across conditions presenting with acute episodes and is considered relevant for easing symptoms linked to organ-specific functional stress, such as bone loss.

“The primary goal of this therapy is to help patients cope more steadily with symptom fluctuations and support general well-being during symptomatic phases.”

It is relevant in conditions characterized by periods of heightened symptoms, and may assist with managing symptoms linked to organ-specific functional stress, such as bone loss. Overall, Novofem helps provide supportive relief that assists with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Eligibility and Restrictions for Use

Novofem is officially indicated for postmenopausal women with an intact uterus who are experiencing estrogen deficiency symptoms. Eligibility generally requires a period of at least six months since the last natural menses. The experience of treating women over 65 years is limited.

Contraindicated Populations (Must Not Use)

Official regulatory documents stipulate that Novofem is contraindicated (absolutely excluded) for individuals with:

  • Known or suspected breast cancer or any estrogen-dependent malignant tumors (e.g., endometrial cancer).
  • Undiagnosed genital bleeding or untreated endometrial hyperplasia (excessive uterine lining growth).
  • Current or previous venous thromboembolism (blood clots in the veins) or arterial thromboembolic events (e.g., heart attack, stroke).
  • Known thrombophilic disorders (inherited clotting defects).
  • Active liver disease or a history of liver disease where function has not normalized.
  • Known pregnancy or while breastfeeding.

Conditional Use (Requires Close Supervision)

Patients with certain pre-existing conditions, such as uterine fibroids, endometriosis, hypertension, diabetes, epilepsy, or cardiac/renal dysfunction, must be closely supervised during treatment, as these conditions may be aggravated or recur.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Novofem (estradiol/norethisterone acetate) is predominantly defined by pharmacokinetic alterations affecting the concentration of the active hormonal components. These interactions stem primarily from the involvement of Cytochrome P450 (CYP) enzymes in the liver's metabolic clearance pathway.

Medicines that are strong inducers of CYP3A4 metabolism are documented to reduce the plasma concentrations of oestrogen, potentially diminishing the expected effect. Conversely, co-administered CYP3A4 inhibitors may cause an increase in the circulating plasma concentrations of both hormonal components. The estradiol component can also act as an inhibitor of CYP1A2, which may lead to an increase in the plasma levels of co-administered drugs that are substrates for that enzyme.

Food, Supplements, and Lifestyle Substance Interactions

Substance Officially Documented Interaction Outcome
Grapefruit Juice May increase the bioavailability of oral estrogens by inhibiting first-pass metabolism.
Alcohol (Acute) Has been documented to increase circulating estradiol levels.
Cigarette Smoking Poses a significant increased risk for serious cardiovascular events and is a major restriction with estrogen use.

Population-Specific Considerations

Close monitoring is required for patients with advanced renal impairment because the circulating levels of the active hormonal components are expected to be increased due to the alteration in clearance. No specific drug-drug combinations are formally listed as contraindicated solely due to interaction risk in the official product information.

Mechanism of Action

Novofem is a combination sequential preparation containing estradiol and norethisterone acetate. The mechanism of action is mediated through the two components' interactions with specific nuclear receptors in target tissues, primarily the reproductive tract, bone, and central nervous system.

Estradiol, a synthetic 17beta-estradiol, acts as an agonist for the Estrogen Receptors (ERs), including ERalpha and ERbeta. Upon binding, the activated receptor-ligand complex translocates to the nucleus, dimerizes, and binds to Estrogen Response Elements (EREs) on the DNA. This interaction modulates the transcription of target genes, leading to changes in protein synthesis and cellular function in estrogen-responsive tissues. In bone, this cascade decreases bone turnover via modulation of osteoclast activity, influencing systemic bone mineral density.

Norethisterone acetate is a progestagen that is rapidly converted to the active compound, norethisterone, which acts as a potent agonist for the Progesterone Receptor (PR). Progestagen binding to PRs leads to nuclear translocation and gene transcription modulation via Progesterone Response Elements. In the endometrium, the sequential administration of norethisterone acetate opposes the proliferative effects induced by estradiol by decreasing ER levels and inducing a secretory differentiation of the tissue. This coordinated dual-hormone signaling modulates the overall physiological state of hormone-sensitive systems.

Dosage and Administration Information

How Novofem is Used: Official Administration Guidelines

Novofem is a continuous sequential combined preparation for Hormone Replacement Therapy (HRT) intended for postmenopausal women with an intact uterus. Its usage strictly follows a defined 28-day regimen based on regulatory prescribing information.


Administration and Dosing Schedule

The medicine is supplied as two types of film-coated tablets in a 28-day calendar pack. It is administered exclusively by the oral route.

Instruction Detail
Route of Administration Oral (swallowed whole with liquid).
Standard Daily Dose One tablet once daily without interruption.
Dosing Regimen Days 1–16: One red tablet (1 mg Estradiol) daily. Days 17–28: One white tablet (1 mg Estradiol / 1 mg Norethisterone acetate) daily.
Timing Tablets should be taken at approximately the same time each day.
With Food Can be taken with or without food and drink.

Procedural Instructions

Treatment is continuous. The tablets must be taken in the sequential order indicated in the calendar pack. A new 28-day pack is started immediately after completing the last tablet of the previous pack.

Missed Dose: If a tablet is forgotten, it must be taken as soon as possible within the next 12 hours. If more than 12 hours have passed, the missed tablet should be discarded, and the user must resume the normal schedule with the next tablet to avoid a double dose. Discarding a tablet may lead to breakthrough bleeding.

Dose Adjustment: The official guidance recommends using the lowest effective dose for the shortest duration necessary for symptom management. The need for continued therapy should be re-evaluated periodically (e.g., at least annually) by a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of how research has investigated patient comfort and evaluated changes in the severity of common postmenopausal symptoms.


Drug A and Drug B Combination

Research has examined the combination of Drug A (estradiol) and Drug B (norethisterone acetate). This formulation is a continuous sequential Hormone Replacement Therapy (HRT) studied in women with an intact uterus who are postmenopausal (at least six months since last menses).

Primary Study Outcomes

Clinical trials have explored whether combining the two active ingredients is associated with changes in menopausal symptoms, particularly vasomotor symptoms (hot flushes and night sweats).

Studies investigated key endpoints relevant to estrogen deficiency, including:

  • Frequency and severity of hot flushes and night sweats.
  • Bone mineral density (BMD) for the prevention of osteoporosis in high-risk groups.
  • Patient-reported quality of life (QoL) scores.

Administration Protocols Studied

Research evaluated one specific administration protocol, which involved a continuous dose of estradiol and a progestagen component added sequentially for 12 days of the 28-day cycle. Studies focused on doses of Estradiol (1 mg) and Norethisterone Acetate (1 mg).


Secondary Research Areas and Risk Data

Epidemiological studies and large clinical trials have consistently established the risks associated with systemic HRT. The progestagen component (norethisterone acetate) is included to counteract the increased risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen use in women with a uterus.

Additional research has investigated the relationship between combined HRT and the risk of venous thromboembolism (VTE), stroke, and breast cancer, noting that the increased risks are generally dependent on the duration of use and the patient's age and baseline health profile.

Frequently Asked Questions (FAQ)

Common questions about Novofem (FAQ)


Q: What is the main difference between Novofem and other types of HRT?

Novofem is classified as a continuous sequential combined Hormone Replacement Therapy (HRT) regimen. This structure is designed to result in a monthly withdrawal bleed, which is the main difference compared to continuous combined HRT regimens that typically aim to be bleed-free.


Q: Can Novofem affect your mood or emotional stability?

According to regulatory documents, effects on emotional stability are a possibility. Official product information lists depression and mood changes among the potential side effects associated with the use of HRT. As with any medicine, individual experiences may vary.


Q: How long is Novofem typically prescribed for?

Official regulatory guidance states that Novofem should be used at the lowest effective dose for the shortest duration necessary for symptom management. The need for continued therapy is generally re-evaluated periodically by a healthcare professional, such as on an annual basis.


Q: What are the reasons someone might stop taking Novofem?

The medicine must be stopped if certain serious conditions occur, such as suspected breast or endometrial cancer, unexplained vaginal bleeding, or the occurrence of a venous blood clot. These situations are described in regulatory information as requiring discussion with a healthcare provider immediately.


Q: Why is Novofem sometimes prescribed instead of continuous combined HRT?

Sequential combined HRT, like Novofem, is often selected for women with an intact uterus who prefer or require a regular, predictable monthly withdrawal bleed pattern. This is the key distinction compared to the continuous combined regimen where the goal is typically to avoid bleeding.


Q: Is Novofem used to treat conditions other than menopause symptoms?

Yes, authoritative documents also indicate Novofem for the prevention of osteoporosis in certain postmenopausal women. This is specified for those who are at high risk of future fractures and who may not be able to use other approved products for prevention.


Q: Do studies suggest Novofem improves bone density?

Studies have examined the use of the active hormonal components. Research suggests the estradiol component may help prevent postmenopausal loss of bone minerals and has been associated with increases in bone mineral density.


Q: Is it mandatory to use Novofem for a minimum length of time?

There is no mandatory minimum length of use defined in the official guidance. Treatment length is individualized and focused on using the medication for the shortest duration necessary to control menopausal symptoms.


Q: Can Novofem be used if you have a family history of blood clots?

A family history of clotting disorders is noted in authoritative information as a risk factor that requires consideration for blood clots. The medicine is strictly contraindicated for individuals who have known thrombophilic disorders (inherited clotting defects).


Q: Is Novofem a type of birth control?

No, Novofem is specifically intended for use in postmenopausal women to address oestrogen deficiency symptoms. It is not indicated for use as a contraceptive (birth control) medication.


Q: How quickly do the effects of Novofem usually start to be noticed?

According to official product information, relief of postmenopausal symptoms is generally achieved during the first few weeks of treatment. Efficacy is often clinically assessed after approximately three months of use.


Q: Can Novofem make existing conditions like migraines worse?

Headaches are a common side effect of HRT, as noted in regulatory information. Official information states that developing migraine-like headaches for the first time is a reason to discuss treatment with a healthcare provider.


Q: What should a patient do if they have concerns about a possible side effect?

Regulatory patient information indicates that patients who experience side effects may consult their doctor or pharmacist. This guidance applies to all possible adverse reactions, including those not specifically listed in the official patient leaflet.


Q: Can herbal remedies, like St. John's Wort, affect how Novofem works?

The hormonal components are metabolized by liver enzymes, specifically Cytochrome P450 (CYP) enzymes. Herbal products such as St. John's Wort are known to induce (speed up) these enzymes and may potentially reduce the concentration of hormones in the blood, possibly diminishing the expected effect.


Q: Is Novofem associated with hair loss or hair thinning?

Hair loss is listed in regulatory information as a possible adverse reaction associated with the medicine. A healthcare provider can be consulted if there are concerns about this or any other side effect.


Q: Can taking Novofem be stopped abruptly?

Regulatory patient information indicates that discussion with a doctor is appropriate if considering stopping the medicine. Abrupt discontinuation may result in the return of menopausal symptoms.


Q: Does Novofem have an effect on cholesterol levels?

Studies on the active ingredients have indicated an effect on blood lipids. Research indicated an association with a reduction in total cholesterol and LDL cholesterol (often referred to as 'bad' cholesterol).


Q: Does Novofem impact libido?

Changes in libido (sexual desire) are listed in regulatory information as a possible side effect of the medicine.

How should Novofem be stored and disposed of?

How to Store and Dispose of Novofem

Novofem (Estradiol and Norethisterone acetate) must be stored and handled according to specific regulatory requirements to maintain its stability.


Official Storage Conditions

Requirement Description
Temperature Constraint Store the tablets below 25°C (Do not store above 25°C).
Environmental Protection Must be protected from light and moisture.
Container Integrity Keep the medicine in the original outer carton.
Safety Precaution Keep the product out of the sight and reach of children.

Official Disposal Rules

Unused or expired Novofem must not be disposed of via wastewater or household waste to protect the environment. Disposal should be carried out strictly according to local requirements, typically involving return to a pharmacist or a designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novofem found in:

A-Z Index: